10x Genomics, Inc. with ticker code (TXG) have now 12 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between 75 and 30 calculating the mean target price we have $62.75. Now with the previous closing price of $49.73 and the analysts are correct then we can expect a percentage increase in value of 26.2%. It’s also worth noting that there is a 50 day moving average of $53.58 and the 200 day moving average is $49.67. The market cap for the company is 5.42B. The stock price for the company is currently 46.19 USD
The potential market cap would be $6,843,493,993 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of 4.93 and a -11.2% return on assets.
10x Genomics, Inc. is a life science technology company. The Company’s integrated platform solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, Visium Spatial Proteogenomics and Xenium In Situ Gene Expression. Its patent portfolio comprises over 1,750 issued patents and patent applications.
